PSI researchers identify potential active agent against several unicellular parasites – including the pathogens that cause malaria and toxoplasmosis.
PSI researchers have developed a new method to attach proteins to the surface of virus-like particles.
The University Hospital of Zurich uses proteins made at PSI for Europe’s first large-scale serology study on coronavirus prevalence in Switzerland.
A research consortium has deciphered the mechanism of CCR5 receptor activation, providing insights for the development of CCR5 drug antagonists for AIDS, cancer, and inflammatory diseases.
Using a combination of computer simulations and laboratory experiments, PSI researchers have identified new binding sites for active agents on the vital protein tubulin.
In our bodies, G protein-coupled receptors mediate countless processes. PSI researcher Ramon Guixà talks about how he brings those receptor molecules to life on the computer screen.
Imaging and sequencing techniques combined with machine learning offer researchers countless opportunities to look inside cells with greater precision than ever before. G.V. Shivashankar, lab head at PSI, describes how such information can be used to find answers to pressing questions.
Measurements at the Swiss Light Source SLS have helped to understand how the only known natural protein-mineral crystal is formed. It is part of the fascinating glass skeleton of sponges.
The European Research Council (ERC) is funding an interdisciplinary collaborative project with 10 million euros for the structural and biophysical analysis of selected photoreceptors and their development into "OptoGPCRs", light-controlled molecular switches with a wide range of applications in biology and medicine.
At PSI, researchers decipher the structure of the proteins in bacteria and viruses. This knowledge can aid, for example, in the development of drugs against infectious diseases. But before the investigation can begin, an extremely tricky problem has to be solved: the crystallisation of the molecules.
PSI congratulates Emmanuelle Charpentier and Jennifer Doudna on winning this year's Nobel Prize in Chemistry. Experiments at the Swiss Light Source SLS in 2013 made it possible to elucidate the structure of the protein complex CRISPR-Cas9.
The world of microbes and viruses is extremely old and exceedingly diverse. With the large research facilities at PSI, researchers are peering deep inside this alien cosmos and investigating, above all, the proteins of these exotic beings.
At PSI, researchers are screening molecule fragments to see if these bind to important proteins of the coronavirus SARS-CoV-2 and thus have the potential to disable it. They are hoping the many individual pieces of information will yield an answer as to what an effective drug might look like.
SARS-CoV-2 might be transmitted via aerosols, that is, through the air. Researchers point this out in the journal Clinical Infectious Diseases. André Prévôt from PSI co-signed the publication. In this interview, he explains which precautionary measures he recommends.
Frankfurt scientists identify a possible weakness of the SARS-CoV-2 virus. They carried out part of their measurements at PSI's Swiss Light Source SLS. The research results are published this week in the scientific journal Nature.
Researchers at the Paul Scherrer Institute PSI have succeeded for the first time in recording a light-driven sodium pump from bacterial cells in action. The findings promise progress in developing new methods in neurobiology. The researchers used the new X-ray free-electron laser SwissFEL for their investigations.
PSI researchers simulate and model large research facilities as well as experiments, for example, in the materials and biological sciences. Andreas Adelmann, head of PSI's Laboratory for Scientific Computing and Modelling, explains how they do it.
Researchers in PSI's Laboratory for Scientific Computing and Modelling solve the most complex problems through a combination of theory, modelling, and high-performance computing. With powerful computers, they simulate the smallest molecules or large research facilities.
In the service of health, scientists at the Paul Scherrer Institute PSI work with radionuclides and develop agents to treat cancer and to detect tumours. Their research provides support to hospitals and is of great interest to Swiss industry.
At the treatment stations of the Centre for Proton Therapy at PSI, tumours can be precisely irradiated from any direction. An interactive graphic explains how the protons get from the source to the body in order to trigger the elimination of tumour tissue.